Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); Top-Line Phase III Results From GALA Study
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Analyst, Randall Stanicky, said, "TEVA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Randall Stanicky, said, "TEVA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
